Immunome, Inc. · NASDAQ:IMNM

Immunome — Investor Presentation (June 2022)

31 slides from Immunome's investor presentation, Jun 9, 2022

  1. Slide 1: Harnessing the Power of the Human Memory B Cell

    Harnessing the Power of the Human Memory B Cell June 9, 2022 Immunome, Inc. 665 Stockton Drive, Suite 300 | Exton, PA 19341 610.321.3700 | www.immunome.com Copyright © 2022 Immunome, Inc. All rights reserved.

  2. Slide 2: Disclaimers and Forward-Looking Statements

    Disclaimers and Forward-Looking Statements This presentation includes certain disclosures that contain “forward-looking statements” All statements contained in this presentation are made as of the date specified on the intended to qualify for the “safe harbor” from liability established by the Priva

  3. Slide 3: Immunome "At a Glance"

    Immunome “At a Glance” INFECTIOUS DISEASES IMM-BCP-01 Treatment of COVID-19 Topline Data • Continues to maintain effectiveness against emerging variants in 2H 2022 preclinical testing • Current antibody therapies are limited; FDA continues to grant Proprietary Platform • Emergency Use Authorizations

  4. Slide 4: Immunome Development Pipeline

    Immunome Development Pipeline INFECTIOUS PRODUCT CANDIDATE ANTICIPATED DISEASES TARGET DESCRIPTION DISCOVERY PRECLINICAL PHASE 1B MILESTONE Three SARS- Three antibody Topline Data in IMM-BCP-01 CoV-2 cocktail 2H 2022 Epitopes PRODUCT CANDIDATE ANTICIPATED ONCOLOGY TARGET DESCRIPTION DISCOVERY PRECLI

  5. Slide 5: We See the Disease Through the Lens of a Memory B-cell

    We See the Disease Through the Lens of a Memory B-cell Interrogate Most Educated Components of Immune Response in an Unbiased Manner at Industrial Scale Multiple Patients Blood, Lymph nodes Ongoing access to new and diverse and tumor tissue patient memory B cells Immortalizing B-cell Response Propri

  6. Slide 6: Infectious Diseases: IMM-BCP-01

    Infectious Diseases: IMM-BCP-01 Collaboration with U.S. DoD & DHA for IMM-BCP-01 Program, Awarded Up to $17.6M in Funding* * OTA: W911QY-20-9-0019 Copyright © 2022 Immunome, Inc. All rights reserved.

  7. Slide 7: IMM-BCP-01: Three Antibody Cocktail for the Treatment of COVID-19

    IMM-BCP-01: Three Antibody Cocktail for the Treatment of COVID-19 IMM-BCP-01 three In vitro preclinical In vitro neutralization Identified Antibodies antibody cocktail neutralization of variants translates into in vivo from SARS-CoV-2 patient designed to retain that have emerged efficacy in infected

  8. Slide 8: IMM-BCP-01: Poised to Be a Critical Player in the Management of the Pandemic

    IMM-BCP-01: Poised to Be a Critical Player in the Management of the Pandemic SELECT PANDEMIC RESPONSE NEEDS IMM-BCP-01 ADVANTAGES DIMENSIONS Pre-clinical efficacy against all CDC variants of EMERGING VARIANTS New variants evade existing therapies concern* Sub-potent treatments can result in escape T

  9. Slide 9: Emerging Variants Change the COVID Landscape

    Emerging Variants Change the COVID Landscape Variants will likely continue to emerge and rapidly change the landscape of infections Omicron Omicron emerged as a highly divergent variant • Detected in November ’21 and rapidly displaced Delta as the dominant circulating strain • Omicron sub-lineages n

  10. Slide 10: COVID-19 Antibody Therapies Will Remain Critical

    COVID-19 Antibody Therapies Will Remain Critical Multiple therapeutic approaches will be needed despite vaccination Efficacy Against Omicron Sub-Lineages3 • Monoclonal antibodies and oral agents Ab Neutralization Post-Vaccination Neutralization Titers Titers Oral agents are primarily used in the tre

  11. Slide 11: Emerging Variants Shape the COVID Antibody Market

    Emerging Variants Shape the COVID Antibody Market ? EUA Granted LLY6 AZ5 80 Variant Alpha Beta GSK/VIR4 Gamma Delta 60 MUTATIONS Omicron BA.1 REGN2 LLY3 Omicron BA.2 Omicron BA.2.12 LLY1 40 GSK/VIR4 1. Bamlanivimab (https://www. fda.gov/media/147629/dow EUA Revoked/Limited nload) 20 LLY 3 2. REGN-Co

  12. Slide 12: IMM-BCP-01 Neutralizes Virus Utilizing Different Mechanisms

    IMM-BCP-01 Neutralizes Virus Utilizing Different Mechanisms Induces Protease Sensitive Conformation* CONFORMATIONAL Spike Spike + ACE2 Spike + IMM20253 Spike + IMM20190 CHANGE AND S DESTABILIZATION* - 15 60 - 15 60 - 15 60 15 60 2 (S1 +S2) IMM20253 S2 1 ACE2 IMM20190 BLOCKADE + IMM20184 Competes ACE

  13. Slide 13: IMM-BCP-01 Induces Multiple Viral Clearance Mechanisms In Vitro

    IMM-BCP-01 Induces Multiple Viral Clearance Mechanisms In Vitro Viral Clearance Mechanisms are Critical to Therapeutic Efficacy Loss of Fc Driven Effector Function In Vitro Data Shows Potential for Multiple Viral Decreases In Vivo Activity Clearance Mechanisms In Vivo Literature demonstrates that mu

  14. Slide 14: IMM-BCP-01 Continues to be Active Against the Omicron Variants

    IMM-BCP-01 Continues to be Active Against the Omicron Variants In vitro Neutralization of Omicron BA.1 and In vitro Neutralization Translates into Robust BA.2 in Live Virus Testing1 Viral Load Reduction in Hamster Model 1 Omicron BA.1 Cmax2 Log [Ab], nM Vehicle IMM-BCP-012 1. Immunome internal data

  15. Slide 15: IMM-BCP-01: Poised to Be a Critical Player in the Management of the Pandemic

    IMM-BCP-01: Poised to Be a Critical Player in the Management of the Pandemic SELECT PANDEMIC RESPONSE NEEDS IMM-BCP-01 ADVANTAGES DIMENSIONS Pre-clinical efficacy against all CDC variants of EMERGING VARIANTS New variants evade existing therapies concern* Sub-potent treatments can result in escape T

  16. Slide 16: Oncology

    Oncology Copyright © 2022 Immunome, Inc. All rights reserved.

  17. Slide 17: B cells: Critical Players in Tumor Immunity

    B cells: Critical Players in Tumor Immunity B Cells T Cells Macrophages Dendritic Cells Survival in Melanoma patients • B cell infiltration more closely associated with survival than T cell presence in multiple cancers • Therapeutic success of IO therapies is associated with coordinated response inc

  18. Slide 18: Platform Maps Diverse Memory B-cell Repertoire Against Cancer

    Platform Maps Diverse Memory B-cell Repertoire Against Cancer Highly Productive Platform Operating at Industrial Scale CANCER TYPES INTERROGATED Diverse Cancer Landscape Other 12% 14 >350 ~140 ~250K Renal 7% Breast 38% H&N 9% Cancers Patients Libraries Hybridoma Lung 13% *Source tissues include LN,

  19. Slide 19: Immunome Oncology R&D Pipeline

    Immunome Oncology R&D Pipeline Targets Identified from Authentic Human Immune Response Program Novel Immune Modulators Potential Cancers of Relevance Format IMM-ONC-01 Neutralize apoptotic tumor cells derived IL-38; recruit and Lung, head & neck, gastroesophageal mAb (Anti-IL-38) activate immune cel

  20. Slide 20: IMM-ONC-01 Anti IL-38 Antibody

    IMM-ONC-01 Anti IL-38 Antibody Copyright © 2022 Immunome, Inc. All rights reserved.

  21. Slide 21: Growing Evidence of IL-38 as a Key Immune Modulator

    Growing Evidence of IL-38 as a Key Immune Modulator &\WRNLQH Contents lists available at cienceDirect Cytokine journal homepage: www.elsevier.com/locate/cytokine Interleukin-38 in Health and Disease Dennis M. de Graaf a, b, *, Lisa U. Teufel b, Leo A.B. Joosten b, c, Charles A. Dinarello a, b a Depa

  22. Slide 22: IMM-ONC-01 Anti IL-38 Antibody

    IMM-ONC-01 Anti IL-38 Antibody Anti IL-38 Antibody Therapy has Potential to Be an Important Advancement in Cancer Care Blocking IL-38 in Preclinical Testing Appears to Enable the Immune System to Fight Cancer IL-38, a novel cancer Blocking IL-38 leads IL-38 dampens to tumor control in IND filing tar

  23. Slide 23: IL-38 Proposed Role in Cancer

    IL-38 Proposed Role in Cancer Tumor Cell-derived IL-38 Suppresses Innate Activation Tumor Cells Secrete IL-38 Upon IL-38 Therapeutic Hypothesis Apoptosis Induction • IL-38 secretion associated with apoptotic cell death1 1. Inhibit immune • Acts during tissue damage to limit unwanted immune Infiltrat

  24. Slide 24: IL-38 Expression in Solid Tumors

    IL-38 Expression in Solid Tumors IL-38 Expression Confirmed in Multiple Tumors of High Unmet Medical Need (Source: Tempus Real-World Data) IL-38 protein expression in HNSCC aligns with IL-38 is Expressed in Multiple Tumors transcriptional data* Tumor versus Healthy Adjacent Tissue Expression Patholo

  25. Slide 25: IL-38 Expression is Associated with Reduced Immune Cell Infiltration

    IL-38 Expression is Associated with Reduced Immune Cell Infiltration IL-38 Overexpression Inhibits Infiltration High IL-38 Expression is Associated with of T cells into Tumors In Vivo Reduced Immune Cell Infiltration* • IL-38 high tumor samples correlate with reduced infiltration of multiple immune

  26. Slide 26: IMM-ONC-01 Anti IL-38 Antibody: Tumor Control in Two Models

    IMM-ONC-01 Anti IL-38 Antibody Blocking IL-38 Leads to Tumor Control in Two Different Tumor Models* Demonstration of Anti-Tumor Activity Induction of Anti-Tumor Memory (B16F10 Model) (EMT6 Model) • Immunologically cold tumor model • ~40% response rate upon treatment with IMM-ONC-01 • IMM-ONC-01 sign

  27. Slide 27: Oncology Platform and Research Pipeline

    ONCOLOGY Platform and Research Pipeline Copyright © 2022 Immunome, Inc. All rights reserved.

  28. Slide 28: Discovery Engine Identified Multiple Processes Driving Cancer Progression

    Discovery Engine Identified Multiple Processes Driving Cancer Progression 1. Membrane Dynamics/Exosomes Elevated cell motility associated invasion and metastasis • IMM20059 (anti EPN1 antibody) 2. Metabolism Immune Modulation High demand for materials supporting rapid tumor expansion Novel Targets 3

  29. Slide 29: Discovery Engine Also Identified Multiple Target Features

    Discovery Engine Also Identified Multiple Target Features Several Proteins Ectopically (Abnormally) Expressed On Cancer Cells – Multiple ADC Targets Across Clusters Diverse B Cell Clones Targeting Unique Features on Cancer Cells Applicable Across Broad Cancer Indications NORMAL CANCER Ectopic expres

  30. Slide 30: Immunome Oncology R&D Pipeline

    Immunome Oncology R&D Pipeline Targets Identified from Authentic Human Immune Response Program Novel Immune Modulators Potential Cancers of Relevance Format IMM-ONC-01 Neutralize apoptotic tumor cells derived IL-38; recruit and Lung, head & neck, gastroesophageal mAb (Anti IL-38) activate immune cel

  31. Slide 31: Immunome "At a Glance"

    Immunome “At a Glance” INFECTIOUS DISEASES IMM-BCP-01 Treatment of COVID-19 Topline Data • Continues to maintain effectiveness against emerging variants in 2H 2022 preclinical testing • Current antibody therapies are limited; FDA continues to grant Proprietary Platform • Emergency Use Authorizations

Immunome — Investor Presentation (June 2022) on 6ix